Related Experiment Video
Updated: May 4, 2026
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
Published on: March 11, 2020
An experimental model for Huntington's chorea?
Dagmar H Zeef1, Ali Jahanshahi1, Rinske Vlamings2
1Department of Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands; European Graduate School of Neuroscience (EURON) , The Netherlands.
Insights
This study validates a transgenic rat model for Huntington's disease (HD) chorea. Tetrabenazine effectively reduced hyperkinetic movements, confirming the model's utility for studying choreiform movement disorders.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Huntington's disease (HD) is characterized by chorea, a hyperkinetic motor disorder.
- A transgenic rat model exhibiting hyperkinetic movements is the only known experimental model for HD chorea.
Purpose of the Study:
- To characterize hyperkinetic movements in the transgenic HD rat model.
- To investigate the efficacy of tetrabenazine (TBZ) in mitigating these movements.
Main Methods:
- Detailed assessment and characterization of hyperkinetic movements in transgenic HD rats.
- Administration of tetrabenazine (TBZ) to evaluate its therapeutic effect.
Main Results:
- The observed hyperkinetic movements met clinical-behavioral criteria for choreiform disorder.
- Tetrabenazine significantly reduced the frequency of these hyperkinetic movements.
Conclusions:
- The transgenic HD rat model exhibits genuine choreiform movement disorder.
- This model is a valuable tool for research into chorea and its treatment.
Abstract:
Clinically, Huntington's disease (HD) is well known for the predominant motor symptom chorea, which is a hyperkinetic motor disorder. The only experimental model currently described in the literature, as far as we are aware of, exhibiting hyperkinetic movements is the transgenic rat model of HD. We assessed and characterized these hyperkinetic movements in detail and investigated the effect of tetrabenazine (TBZ) treatment. TBZ is an effective drug in the treatment of chorea in HD patients. Our results showed that the hyperkinetic movements fulfilled the clinical-behavioral criteria of a choreiform movement. Administration of TBZ reduced the number of these hyperkinetic movements substantially. These findings suggest that the hyperkinetic movements observed in this animal model can be considered as a choreiform movement disorder. This makes these animals unique and provides opportunities for chorea-research.
